The content on this site is intended for healthcare professionals only
Dr Olga Guryanova presents, at a press conference at EHA 2015, the findings of her work looking at the role of mutant DNMT3A in acute myeloid leukaemia (AML) pathogenesis and chemoresistance.
Read the news story for more.
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types
New classification for identifying HR myeloma based on cytogenetic abnormalities
Revolutionising myeloma treatment through immune profiling
Addressing the rise of multiple myeloma in Rwanda
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
